(BTTX) – Company Press Releases
-
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
-
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
-
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies &
-
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
-
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
-
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
-
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
-
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
-
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
-
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award
-
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
-
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023
-
Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference
-
Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes
-
Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes
-
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
-
Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes
-
Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023
-
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
-
Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes
-
Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria
-
Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
-
Better Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
-
Better Therapeutics Announces $6.5MM Private Placement
-
Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
-
Better Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023
-
Better Therapeutics to Participate in Two Upcoming Investor Conferences
-
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
-
Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Better Therapeutics to Participate in BTIG Digital Health Forum
-
Better Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Better Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022
-
Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer
-
Positive Results from Pivotal Trial of Better Therapeutics’ Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care
-
Better Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes
-
Better Therapeutics to Participate in Three Upcoming Investor Conferences
-
Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Better Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
-
Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results
-
Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
-
Better Therapeutics Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001, a Novel Prescription Digital Therapy, in Clinica
-
Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
-
Better Therapeutics to Participate in Cowen’s Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022
-
Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform
-
Better Therapeutics Appoints Frank Karbe as Chief Executive Officer
-
Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabetes Association Guidelines Recommending Digital Tools in Diabetes Care
-
Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones
-
Better Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 13, 2022
Back to BTTX Stock Lookup
